Selected References:
- Ghafuri, DL, et al. 2017. Fertility challenges for women with sickle cell disease. Expert review of hematology, 10(10), 891–901.
- Food and Drug Administration. 2019 HIGHLIGHTS OF PRESCRIBING INFORMATION: OXBRYTA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf.
- Food and Drug Administration. 2019. FDA approves voxelotor for sickle cell disease. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-voxelotor-sickle-cell-disease.
- Osegbe, DN, et al. 1981. Fertility in males with sickle cell disease. Lancet (London, England), 2(8241), 275–276.
- Patel ZV, et al. 2024. Newer Modalities and Updates in the Management of Sickle Cell Disease: A Systematic Review. J Blood Med. 12;15:435-447. doi: 10.2147/JBM.S477507. PMID: 39286637; PMCID: PMC11404495.
- Pecker, LH; Kuo, KH.2022. Go the Distance: Reproductive Health Care for People with Sickle Cell Disease. Hematology/oncology clinics of North America, 36(6), 1255–1270.
- Rogers, DT; Molokie, R. 2010. Sickle cell disease in pregnancy. Obstetrics and gynecology clinics of North America, 37(2), 223–237.
- Serjeant, GR et al. 2004. Outcome of Pregnancy in Homozygous Sickle Cell Disease. Obstetrics & Gynecology 103(6):p 1278-1285.
